Global life sciences leader, Cytiva, is bringing solutions to the challenges of viral vector-based gene therapies. The company has created three cell lines for adeno-associated virus (AAV) production.

AGC Biologics strengthens access to world-class biomanufacturing in Japan with two Cytiva FlexFactory manufacturing platforms at its new production line in Yokohama, Japan

Cytiva unveils the Xcellerex magnetic mixer, a single-use mixing system specifically designed to address challenges faced during large-scale mAb, vaccine, and genomic medicine manufacturing processes.

Global life sciences leader, Cytiva, is bringing solutions to the challenges of viral vector-based gene therapies. The company has created three cell lines for adeno-associated virus (AAV) production.

AGC Biologics strengthens access to world-class biomanufacturing in Japan with two Cytiva FlexFactory manufacturing platforms at its new production line in Yokohama, Japan

Cytiva unveils the Xcellerex magnetic mixer, a single-use mixing system specifically designed to address challenges faced during large-scale mAb, vaccine, and genomic medicine manufacturing processes.